Related Experiment Videos
Pleural effusion in lung cancer
1Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston.
Clinics in Chest Medicine
|March 1, 1993
Summary
Pleural effusions in lung cancer patients can be malignant, paramalignant, or unrelated to cancer. For symptomatic patients with malignant effusions and good prognosis, chemical pleurodesis offers effective palliation with minimal risk.
Area of Science:
- Oncology
- Pulmonology
- Thoracic Surgery
Background:
- Pleural effusions frequently complicate lung cancer, often indicating a poor prognosis.
- Distinguishing malignant from paramalignant or unrelated effusions is crucial for treatment planning.
- Malignant pleural effusions (MPEs) significantly impact patient quality of life and survival.
Purpose of the Study:
- To outline the diagnostic approach to pleural effusions in lung cancer.
- To discuss management strategies for malignant pleural effusions.
- To identify optimal palliative treatment for symptomatic MPEs.
Main Methods:
- Review of current literature on lung cancer and pleural effusions.
- Analysis of diagnostic criteria for effusion classification (malignant, paramalignant, benign).
- Evaluation of therapeutic options for symptomatic MPEs, focusing on palliative care.
Main Results:
- Malignant effusions generally preclude curative surgical options.
- Paramalignant effusions require careful evaluation regarding surgical candidacy.
- Chemical pleurodesis is highlighted as a highly effective palliative treatment for symptomatic MPEs in select patients.
Conclusions:
- Accurate classification of pleural effusions in lung cancer is essential for appropriate management.
- For symptomatic patients with MPEs, reasonable life expectancy, and pleural fluid pH > 7.3, chemical pleurodesis is the preferred palliative intervention.
- Timely and appropriate management of MPEs can improve patient quality of life.